

Miller, Diane M. (CDC/NIOSH/EID)

From: Thies, Patrick W. [ThiesPW@crstlukes.com]
Sent: Friday, June 22, 2007 11:05 AM
To: NIOSH Docket Office (CDC)
Subject: 105 - HazDrug Update Comments
Attachments: PublicReviewForm2006-05-01-07.xls

Pat Thies, RPh, MS, FACHE
Director, Pharmacy Services
St. Luke's Hospital
Cedar Rapids, Iowa
(Office) 319-368-5861
(Cell) 319-558-7731
thiespw@crstlukes.com



This message and accompanying documents are covered by the Electronic Communications Privacy Act, 18 U.S.C. §§ 2510-2521, and contain information intended for the specified individual(s) only. This information is confidential. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, copying, or the taking of any action based on the contents of this information is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message.

Drugs to Review 2006 Docket #NIOHS-105

Reviewer :

Affiliation :

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Abilify	aripiprazole		X	
Alimta	pemetrexed		X	
Amevive	alafacept		X	
Amitiza	lubiprostone			
Apokyn	apomorphine HCl		X	
Arranon	nelarabine			
Avastin	bevacizumab		X	
Azilect	rasagiline mesylate		X	
Baraclude	entecavir			
Chantix	varenicline		X	
Clolar	clofarabine			
Cordarone	amiodarone HCl		X	
Dacogen	decitabine	X		
Depacone	valproate Na		X	
Depakene	valproic acid		X	
Depakote	divalproex Na		X	
Depo-Provera**	medroxyprogesterone acetate	X		
Elidel	pimecrolimus	X		
Erbix	cetuximab			
Geodon	ziprasidone		X	
Gleevec	imatinib mesylate			
Hivid	zalcitabine	X		
Hycamtin	topotecan HCl	X		

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer :

Affiliation :

Send reviews to: niocindocket@cdc.gov

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Increlex	mecasermin (rDNA origin)			
Kepivance	palifermin			
Leustatin	cladribine	X		
Lunesta	eszopiclone		X	
Lyrica	pregabalin		X	
Metastron	strontium-89 chloride	X		
Mycamine	micafungin sodium			
Myozyme	alglucosidase alfa			
Nexavar	sorafenib			
Orencia	abatacept			
Paxil	paroxetine HCl		X	
Pentetate Calcium		X		
Trisodium				
Photofrin	porfimer sodium	X		
Provera**	medroxyprogesterone acetate	X		
Quadramet	samarium 153 lexidronam	X		
Rapamune	sirolimus	X		
Revlimid	lenalidomide			
Risperdal Consta**	risperidone		X	
Risperdal**	risperidone		X	
Rituxan	rituximab		X	
Rozerem	ramelteon		X	
Seroquel	quetiapine fumerate		X	

Drugs to Review 2006 Docket #NIOHS-105

Send reviews to: niocindocket@cdc.gov

Reviewer :

Affiliation :

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?	Comments
		yes	no
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs			
Spiriva Handihaler	tiotropium bromide		X
Sprycel	dasatinib		
Sustiva	efavirenz	X	
Sutent	sunitinib malate	X	
Tarceva	erlotinib HCl	X	
Tindamax	tinidazole		X
Tracleer	bosentan	X	
Trileptal	oxcarbazepine		X
Tygacil	tigecycline		X
Tysabri	natalizumab		X
Velcade	bortizomib		
Vidaza	azacitidine	X	
Viramune	nevirapine	X	
Viread	tenofovir	X	
Vision Blue	trypan blue	X	
Zolinza	vorinostat		
Zonegran	zonisamide		
New FDA Drugs and Warnings Not Fitting NIOSH Criteria For Hazardous Drugs			
Actoplus Met	pioglitazone HCl/ metformin HCl		
Actos	pioglitazone HCl		
Adderall	amphetamines		

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer :

Affiliation :

Send reviews to: niocindocket@cdc.gov

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?	Comments
		yes no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs			
Amphadase**	hyaluronidase		
Apidra	insulin glulisine		
Aptivus	tipranavir		
Aranesp	darbepoetin alfa		
	rosiglitazone maleate/		
	glimepiride		
Avandaryl	interferon beta 1a		
Avonex	interferon beta 1b		
Betaseron	exenatide		
Byetta	acamprosate calcium		
Campral	casprofingin acetate		
Candidis	human secretion		
ChIRhoStim	clozapine		
Clozaril	methylphenidate HCl		
Concerta*	duloxetine HCl		
Cymbalta	methylphenidate HCl		
Daytrana*	dextroamphetamine		
Dexedrine	hydromorphone HCl		
Dilaudid	valsartan		
Diovan	idursulfate		
Eliprase	pentosan polysulfate Na		
Elmiron	asparaginase		
Elspar	darifenacin HBr		
Enblex			

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer :

Affiliation :

Send reviews to: niocindocket@cdc.gov

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Epogen**	epoetin alfa			
Eraxis	andulafungin			
Ethylol	amifostine			
Exjade	deferasirox			
Focalin	dexmethphenidate HCl			
Fortovase**	saquinavir mesylate			
Fosrenol	lanthanum carbonate hydrate			
Gabril	tiagabine			
Herceptin	trastuzumab			
Humira	adalimumab			
Hydase**	hyaluronidase			
Invirase**	saquinavir mesylate			
Iplex	mecasermin rinfabate			
Januvia	sitagliptin phosphate			
Ketek	telithromycin			
Lamictal	lamotrigine			
Levemir	insulin detemir			
Lucentis	ranibizumab			
Lumigan	bimatoprost			
Macugen	pegaptanib sodium			
Magnevist	gadopentetate dimeglumine			
Metadate*	methylphenidate HCl			
Methylin*	methylphenidate HCl			

Drugs to Review 2006 Docket #NIOOSH-105

Send reviews to: niocindocket@cdc.gov

Reviewer :

Affiliation :

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?	Comments
		<input type="checkbox"/> <u>yes</u> <input type="checkbox"/> <u>no</u>	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs			
Multihance	gabobenate dimeglumine		
Naglazyme	galsulfase		
Nevanac	nepafenac		
Nexium	esomeprazole magnesium		
Noxafil	posaconazole		
NutreStore	L-glutamine		
Omacor	omega-3-acid ethylesters		
Opana	oxymorphone HCl		
Pentetate Zinc			
Trisodium			
Prevacid NapralPAC	lansoprazole; naproxen		
Prezista	darunavir		
Prialt	ziconotide		
Procrit**	epoetin alfa		
Propranolol HCl			
Ranexa	ranolazine		
Rapamune	sirolimus		
Raptiva	efalizumab		
Remicade	infliximab		
Ritalin*	methylphenidate HCl		
Sanctura	trospium chloride		
Sensipar	cinacalcet HCl		
Serzone	nefazodone HCl		

Drugs to Review 2006 Docket #NIOOSH-105

Send reviews to: niocindocket@cdc.gov

Reviewer :

Affiliation :

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Strattera	atoxetine HCl			
Symlin	pramlintide acetate			
Trasylol	aprotinin			
Tyzeka	telbivudine			
Vectibix	panitumumab			
Ventavis	iloprost			
Veregen	kunecatechins			
VESicare	solifenacin succinate			
Videx	didanosine			
Visudyme	verteporfin			
Vitrase	ovine hyaluronidase			
Welbutrin**	bupropion HCl			
Xifaxan	rifaximin			
Zarontin	ethosuximide			
Zinecard	dextrazoxane			
Zyban**	bupropion HCl			
Zyprexa	olanzapine			

* = several proprietary names for same drug; ** = two proprietary names for same drug

ADDITIONAL COMMENTS